Complix
Diepenbeek
About Complix
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodies™ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodies™ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $26.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Sep 2020)
- Website: complix.com
- Phone: 32 9 241 57 15
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/complix-83475 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.